The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection

Duplančić, Darko; Cesarik, Marijan; Poljak, Nikola Kolja; Radman, Miroslav; Kovačić, Vedran; Radić, Josipa; Rogošić, Veljko

doi:10.2147/cia.s38349

Cited by 13 publications

(8 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paricalcitol, a third generation analogue of vitamin D 2 , is an activator of VDR and is used for secondary hyperparathyroidism. When compared to calcitriol, different effects were observed e.g., a reduced stimulation of the intestinal calcium transport proteins or a reduced effect on calbindin expression [ 52 ]. Similar mechanisms might be responsible for an absent effect on BACE1 expression in the presence of paricalcitol.…”

Section: Resultsmentioning

confidence: 99%

Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation

Grimm

Thiel

Lauer

et al. 2017

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is characterized by extracellular plaques in the brain, mainly consisting of amyloid-β (Aβ), as derived from sequential cleavage of the amyloid precursor protein. Epidemiological studies suggest a tight link between hypovitaminosis of the secosteroid vitamin D and AD. Besides decreased vitamin D level in AD patients, an effect of vitamin D on Aβ-homeostasis is discussed. However, the exact underlying mechanisms remain to be elucidated and nothing is known about the potential effect of vitamin D analogues. Here we systematically investigate the effect of vitamin D and therapeutically used analogues (maxacalcitol, calcipotriol, alfacalcidol, paricalcitol, doxercalciferol) on AD-relevant mechanisms. D2 and D3 analogues decreased Aβ-production and increased Aβ-degradation in neuroblastoma cells or vitamin D deficient mouse brains. Effects were mediated by affecting the Aβ-producing enzymes BACE1 and γ-secretase. A reduced secretase activity was accompanied by a decreased BACE1 protein level and nicastrin expression, an essential component of the γ-secretase. Vitamin D and analogues decreased β-secretase activity, not only in mouse brains with mild vitamin D hypovitaminosis, but also in non-deficient mouse brains. Our results further strengthen the link between AD and vitamin D, suggesting that supplementation of vitamin D or vitamin D analogues might have beneficial effects in AD prevention.

show abstract

Section: Resultsmentioning

confidence: 99%

Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation

Grimm

Thiel

Lauer

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Vitamin D is one of the fat solvent hormones, the most critical work of which is the hemostasis of calcium [10]. Vitamin D deficiency presents in different ways, ranging from nonspecific musculoskeletal pain to definitive clinical presentation of osteomalacia such as pain, tenderness, weakness of muscles, and even difficulty in walking [11,12].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Vitamin D Levels in Patients Presenting With Chronic Low Back Pain at a Tertiary Care Hospital

Kumar¹,

Ahmed²,

Hussain³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Paricalcitol has been demonstrated to suppress inflammation (Duplancic et al, 2013; Navarro-González et al, 2013) as well. In an open-label, prospective pilot trial, Navarro-González et al (2013) studied the effect of oral paricalcitol for 12 weeks in 25 patients on hemodialysis.…”

Section: Discussionmentioning

confidence: 99%

“…In vitro data suggest that vitamin D and its analogs may play a role in endothelial function (Wu-Wong et al, 2005), but very little data are available from in vivo animal and human studies. Preliminary data suggest a reduction in risk factors for cardiovascular disease with paricalcitol compared to other vitamin D related compounds (Duplancic et al, 2013; Gonzalez-Parra et al, 2012; Ortiz, Sanchez Niño, Rojas, & Egido, 2011; Reinhart, 2004; Wu-Wong et al, 2005). …”

Section: Introductionmentioning

confidence: 99%

Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease

Thethi

Bajwa

Ghanim³

et al. 2015

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Aims Patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) have impaired endothelial function. Vitamin D and its analogs may play a role in regulation of endothelial function and inflammation. We studied effects of paricalcitol compared to placebo on endothelial function and markers of inflammation and oxidative stress in patients with T2DM and CKD. Methods A double blind, randomized, placebo-controlled trial was conducted in 60 patients with T2DM and stage 3 or 4 CKD. Paricalcitol 1 mcg or placebo was administered orally once daily for three months. Brachial artery flow mediated dilatation (FMD), nitroglycerine mediated dilation (NMD), and plasma concentrations of inflammatory cytokines, tumor necrosis factor –α and interleukin-6, highly-sensitive C-reactive protein; endothelial surface proteins, intercellular adhesion molecule –1 and monocyte chemo attractant protein-1, and plasma glucose, insulin, free fatty acids, and urinary isoprostane were measured at baseline and end of three months. Results 27 patients in the paricalcitol group and 28 patients in the control group completed the study, though analysis of FMD at both time points was possible in 23 patients in each group. There was no significant difference in the change in FMD, NMD or the biomarkers examined after paricalcitol or placebo treatment. Conclusions Treatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress. The lack of significance may be due to the fact that the study patients had advanced CKD and that effects of paricalcitol are not additive to the effects of glycemic, lipid and anti-hypertensive therapies.

show abstract

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection

Cited by 13 publications

References 72 publications

Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation

Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation

Assessment of Vitamin D Levels in Patients Presenting With Chronic Low Back Pain at a Tertiary Care Hospital

Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease

Contact Info

Product

Resources

About